Bristol Myers Says New Schizophrenia Drug Off to Strong Start
Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, in an early sign that its $14 billion purchase of Karuna Therapeutics is paying off.
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
The stock's rise snapped a three-day losing streak.
Bristol-Myers Squibb Co (BMY) Stock’s -0.01% Decrease This Year: What’s the Story?
Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.74 which represents a slight increase of $0.38 or 0.69% from the prior close of $55.36. The stock opened at $55.5 and touched a low of $55.
Wedmont Private Capital Has $586,000 Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)
Wedmont Private Capital grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 29.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors
This was the stock's third consecutive day of losses.
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the ...
FiercePharma2d
JPM25: BMS, Pfizer and Merck CEOs address key patent cliffs and plans to replace sales
Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.
Positive Outlook for Bristol-Myers Squibb with Promising Market Access and Societal Benefits of Cobenfy
Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...
NBC Connecticut3d
Bristol Myers Squibb CEO describes new drug for treating schizophrenia
Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenfy, which can be used to treat psychiatric ...
Bristol sees annual $1.5B in cost savings by end of 2025
Bristol Myers Squibb CEO Christopher Boerner said $1.5B in annual cost savings should be achieved by the end of the year.
This Unpopular Dividend Stock Is a Buy
This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...
Bristol Myers, ArsenalBio achieve milestone for AB-4000 series
Arsenal Biosciences announced that Bristol Myers Squibb has exercised its exclusive license option for ArsenalBio’s AB-4000 series, the lead collaboration program generated unde ...
CSR Wire3d
Bristol Myers Squibb Named to Dow Jones Sustainability Index North America for Second Consecutive Year
Bristol Myers Squibb announced that it has been named in the prestigious Dow Jones Sustainability Index (DJSI) for the second ...